In vitro susceptibility of cephalothin-resistant enterobacteriaceae andPseudomonas aeruginosa to a one-oxa cephalosporin (LY 127935 or moxalactam), amikacin, and selected cephalosporins

Louie, Milton H.; Meyer, Richard D.; Pasiecznik, Karen A.

doi:10.1007/bf02601810

Cited by 6 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If an investigator suspects a serious infection due to P. aeruginosa, it would be wise to use a consistently more active agent (i.e., an aminoglycoside) until the results of susceptibility tests are known. This concern has also been raised by other investigators (21) and is supported by the results of some in vitro susceptibility studies (2,13).…”

Section: Resultsmentioning

confidence: 71%

Clinical evaluation of moxalactam

Mathisen¹,

Meyer²,

Thompson³

et al. 1982

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Moxalactam was administered intravenously or intramuscularly or both in doses of 1 to 12 g/day to 45 patients with clinically significant infections (17 soft tissue or bone, 9 pleuropulmonary, 9 septicemic, 6 urinary tract, and 4 intraabdominal infections). Mean 0.5-h postinfusion levels were 105 micrograms/ml for a 4.0-g dose, 44.7 micrograms/ml for a 2.0-g dose, and 18 micrograms/ml for a 1.0-g dose. We identified 28 isolates of Enterobacteriaceae, 10 Pseudomonas aeruginosa isolates, 9 Staphylococcus aureus isolates, and 15 anaerobic bacterial isolates. A total of 15 patients were clinically cured, 8 patients improved, 13 patients improved initially but suffered subsequent relapses or superinfections, and 10 patients failed therapy. Toxicity was generally minimal (reversible eosinophilia, and mild liver function abnormalities, and elevated prothrombin time). The selection or emergence of resistant organisms in 17 patients during treatment (particularly Pseudomonas, enterococci, and Candida) was a disturbing feature of therapy. Our results were generally favorable, considering the complicated underlying medical problems of this group of patients.

show abstract

Section: Resultsmentioning

confidence: 71%

Clinical evaluation of moxalactam

Mathisen¹,

Meyer²,

Thompson³

et al. 1982

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Moxalactam has inhibited most commonly occuring gram positive, gram negative, and anaerobic bacteria (50, [182][183][184][185][186][187][188][189][190][191][192][193][194]. It is not clear what should be the level used to defi ne susceptibility, namely 8 p.g/ml or 16 p.g/m!.…”

Section: Microbiologic Activitymentioning

confidence: 99%

The In Vitro Activity, Human Pharmacology, and Clinical Effectiveness of New beta-Lactam Antibiotics

Neu¹

1982

Annu. Rev. Pharmacol. Toxicol.

View full text Add to dashboard Cite

“…Recently, a plethora of new antimicrobial agents has been investigated in order to meet the challenge of increasing resistance and to offer agents with less potential for nephrotoxicity and ototoxicity. Moxalactam, which is a 1-oxa cephalosporin (18) with a broad spectrum of activity against most gram-positive and gram-negative bacteria, including staphylococci and anaerobic organisms (2,6,14,18,24,29), has recently been introduced for clinical use.…”

mentioning

confidence: 99%

In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents

McNamara¹,

Meyer²,

Pasiecznik³

1982

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Amikacin was evaluated in vitro by agar dilution testing against 148 different clinical isolates of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa in parallel with cephalothin, cefoxitin, moxalactam, N-formimidoyl thienamycin, ceftriaxone, and cefmenoxime. Cefsulodin was also evaluated against 39 isolates of P. aeruginosa. More than 80% of all isolates tested were also gentamicin resistant, as determined by disk testing. Moxalactam and amikacin had comparable high activities against Proteus species, Escherichia coli, Serratia species, and Providencia species, and both amikacin and N-formimidoyl thienamycin had comparably high activities against the Klebsiella-Enterobacter group. N-Formimidoyl thienamycin was the most active agent against P. aeruginosa, followed by cefsulodin and amikacin.

show abstract

In vitro susceptibility of cephalothin-resistant enterobacteriaceae andPseudomonas aeruginosa to a one-oxa cephalosporin (LY 127935 or moxalactam), amikacin, and selected cephalosporins

Cited by 6 publications

References 11 publications

Clinical evaluation of moxalactam

Clinical evaluation of moxalactam

The In Vitro Activity, Human Pharmacology, and Clinical Effectiveness of New beta-Lactam Antibiotics

In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents

Contact Info

Product

Resources

About